Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Unity Biotechnology Inc (UBX)

Unity Biotechnology Inc (UBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,842
  • Shares Outstanding, K 16,790
  • Annual Sales, $ 0 K
  • Annual Income, $ -39,860 K
  • 60-Month Beta 0.86
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.03
Trade UBX with:

Options Overview Details

View History
  • Implied Volatility 78.92% ( -40.19%)
  • Historical Volatility 33.82%
  • IV Percentile 27%
  • IV Rank 15.72%
  • IV High 381.51% on 02/01/24
  • IV Low 22.48% on 10/20/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 27
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 1,292
  • Open Int (30-Day) 1,742

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.44
  • Number of Estimates 1
  • High Estimate -0.44
  • Low Estimate -0.44
  • Prior Year -0.85
  • Growth Rate Est. (year over year) +48.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4200 +4.58%
on 05/21/24
1.6700 -11.08%
on 05/07/24
-0.0150 (-1.00%)
since 04/19/24
3-Month
1.4200 +4.58%
on 05/21/24
1.9400 -23.45%
on 03/01/24
-0.2650 (-15.14%)
since 02/21/24
52-Week
1.4200 +4.58%
on 05/21/24
3.8200 -61.13%
on 06/06/23
-1.3450 (-47.53%)
since 05/19/23

Most Recent Stories

More News
Unity (UNX) Down on Disappointing Results From Wet AMD Study

Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.

REGN : 992.80 (+0.56%)
BAYRY : 7.7800 (-1.14%)
UBX : 1.4700 (+3.52%)
Pre-Market Brief: Stocks Move Higher as Investors Brace for Earnings

December S&P 500 futures (ESZ22) are trending up +0.80% this morning after three major US benchmark indices closed lower on Friday as increasing expectations for higher for longer inflation added to the...

ESZ22 : 3,871.47s (-0.66%)
ACOR : 0.6610 (-24.86%)
SDIG : 2.91 (-1.36%)
UNH : 523.19 (+1.15%)
UBX : 1.4700 (+3.52%)
OPEN : 2.26 (-6.61%)
All You Need to Know About UNITY Biotechnology, Inc. (UBX) Rating Upgrade to Strong Buy

UNITY Biotechnology, Inc. (UBX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

UBX : 1.4700 (+3.52%)
Stocks Slip on Weak Chinese Economic Data

Morning Markets September S&P 500 futures (ESU22 ) this morning are down -0.62%. U.S. stock indexes are under pressure today as disappointing economic data from China signals a slowdown in the world’s...

ESM24 : 5,340.75 (+0.17%)
CSCO : 46.65 (-1.02%)
OXY : 63.39 (-0.28%)
HAL : 37.76 (-0.53%)
DVN : 49.82 (-0.40%)
MRO : 26.29 (-0.64%)
FANG : 196.62 (-0.61%)
COP : 120.75 (-0.12%)
FCX : 54.00 (-1.57%)
ITW : 248.69 (-0.76%)
PTON : 3.32 (-15.09%)
TOI : 0.6010 (-1.48%)
UNITY Biotechnology to Present Clinical Data at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting

SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing...

UBX : 1.4700 (+3.52%)
UNITY Biotechnology Reports Granting of New Employment Inducement Award

SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing...

UBX : 1.4700 (+3.52%)
UNITY Biotechnology Announces Appointment of Accomplished Finance and Operations Executive Michael Samar to the Board of Directors

SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to...

UBX : 1.4700 (+3.52%)
UNITY Biotechnology, Inc. Reports First Quarter 2022 Financial Results and Business Updates

-Completed enrollment in BEHOLD, the Phase 2 clinical trial of UBX1325 in DME; BEHOLD remains on track with 12-week safety and efficacy data anticipated by...

UBX : 1.4700 (+3.52%)
UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases

Cellular senescence biology in eye disease was a focal point at ARVO opening symposium...

UBX : 1.4700 (+3.52%)
UNITY Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema

12-week safety and efficacy data anticipated by mid-year 2022 24-week safety and efficacy data anticipated before year-end 2022 SOUTH SAN FRANCISCO,...

UBX : 1.4700 (+3.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company's product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States.

See More

Key Turning Points

3rd Resistance Point 1.5867
2nd Resistance Point 1.5533
1st Resistance Point 1.4867
Last Price 1.4700
1st Support Level 1.3867
2nd Support Level 1.3533
3rd Support Level 1.2867

See More

52-Week High 3.8200
Fibonacci 61.8% 2.9032
Fibonacci 50% 2.6200
Fibonacci 38.2% 2.3368
Last Price 1.4700
52-Week Low 1.4200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar